LAX.SH
DR AGARWALS HEALTH CARE L·Healthcare Companies·Healthcare Services Companies
Price
500.2
-0.58%52W Range
Market Cap
₹15,855.49 Cr
Traded: ₹22.64 Cr (0.14%) 0.0x
Free Float: ₹312.35 Cr (7.25% of FF traded)
Volume · 60D trend
4.53 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +35.0% | +27.0% | -- | +23.0% | Decelerating |
| ROE | -- | +8.0% | +6.0% | -- | -- | Decelerating |
| Return | -- | -- | -- | +8.0% | -- | -- |
| Profit | -- | +34.0% | +13.0% | -- | +43.0% | Stable |
Quarterly Results
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 614 | 564 | 530 | 499 | 487 | 460 | 431 | 417 | 403 | 349 | 333 |
| Expenses | 444 | 403 | 386 | 363 | 360 | 329 | 316 | 310 | 300 | 241 | 244 |
| Operating Profit | 170 | 161 | 144 | 136 | 128 | 131 | 115 | 107 | 104 | 108 | 89 |
| OPM % | 28.0% | 29.0% | 27.0% | 27.0% | 26.0% | 28.0% | 27.0% | 26.0% | 26.0% | 31.0% | 27.0% |
| Other Income | 6 | 14 | 11 | 8 | 13 | 13 | 13 | 12 | 6 | 20 | 12 |
| Interest | 23 | 22 | 21 | 23 | 25 | 25 | 28 | 28 | 27 | 27 | 22 |
| Depreciation | 78 | 77 | 69 | 68 | 63 | 60 | 58 | 57 | 56 | 47 | 43 |
| Profit Before Tax | 75 | 77 | 65 | 54 | 54 | 59 | 41 | 33 | 27 | 54 | 36 |
| Tax % | 27.0% | 35.0% | 33.0% | 32.0% | 29.0% | 27.0% | 31.0% | 36.0% | 33.0% | 24.0% | 37.0% |
| Net Profit | 55 | 50 | 44 | 36 | 38 | 43 | 28 | 21 | 18 | 41 | 23 |
| Exceptional Items | -- | 1 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 1.4 | 1.3 | 1.1 | 0.9 | 0.9 | 1.0 | 0.7 | -- | -- | -- | -- |
| Sales Growth (YoY) | 26.1% | 22.6% | 23.0% | 19.7% | 20.8% | 31.8% | 29.4% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 8.9% | 6.4% | 6.2% | 2.5% | 5.9% | 6.7% | 3.4% | 3.5% | 15.5% | 4.8% | -- |
| OP Growth (YoY) | 32.8% | 22.9% | 25.2% | 27.1% | 23.1% | 21.3% | 29.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 5.6% | 11.8% | 5.9% | 6.3% | -2.3% | 13.9% | 7.5% | 2.9% | -3.7% | 21.3% | -- |
| Profit Growth (YoY) | -- | 14.9% | 51.0% | 79.1% | 150.8% | -12.3% | 12.8% | -- | -- | -- | -- |
| EPS Growth (YoY) | 50.5% | 21.4% | 48.6% | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | 14.4% | 16.8% | 13.8% | -1.1% | -7.8% | 43.1% | -- | -- | -- | -- | -- |
| OP Margin | 27.7% | 28.6% | 27.2% | 27.3% | 26.3% | 28.5% | 26.7% | 25.7% | 25.8% | 30.9% | 26.7% |
| Net Margin | 9.0% | 8.9% | 8.3% | 7.2% | 7.8% | 9.3% | 6.5% | 5.0% | 4.5% | 11.8% | 6.9% |
| Material Cost % | 9.6% | 9.3% | 8.8% | 9.3% | 9.8% | 9.5% | 8.3% | 10.7% | 9.4% | 12.1% | 8.5% |
| Employee Cost % | 19.7% | 18.4% | 19.9% | 19.9% | 19.6% | 18.9% | 19.5% | 19.5% | 18.5% | 16.9% | 19.1% |
| P/S | 7.18 | 7.37 | 7.71 | 7.62 | -- | -- | -- | -- | -- | -- | -- |
| P/E | 106.65 | 114.80 | 120.58 | 124.09 | -- | -- | -- | -- | -- | -- | -- |
| P/B | 7.83 | 7.56 | 7.89 | 7.40 | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DB International Trust (Singapore) Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Claymore Investments (Mauritius) Pte Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hyperion Investments Pte Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Invesco Mutual Fund
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Transcript of the discussion held on the Unaudited Financial Results (Consolidated & Standalone) of the Company for the quarter ended June 30, 2026, at the analyst call held on August 04, ....
Consolidated and Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2026 is submitted.
Outcome of the Meeting of the Board of Directors of the Company held on August 04, 2026, is attached.
Allotment of 43,155 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employee Stock Option Scheme 2022.
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026 is enclosed.
Voting Results and the Consolidated Scrutinizer''s Report on the Hon''ble NCLT convened meeting of the unsecured creditors of Dr. Agarwal''s Health Care Limited held on July 02, 2026, is enclosed.
Voting Results and the Consolidated Scrutinizer''s Report on the Hon''ble NCLT convened meeting of the Equity Shareholders of Dr. Agarwal''s Health Care Limited held on July 02, 2026, is enclosed.
Summary of the Proceedings of the Hon''ble NCLT convened meeting of the Unsecured Creditors of Dr. Agarwal''s Health Care Limited held on July 02, 2026, is enclosed.
Summary of the Proceedings of the Hon''ble NCLT convened meeting of the Secured Creditors of Dr. Agarwal''s Health Care Limited held on July 02, 2026, is enclosed.
Voting Results and the Consolidated Scrutinizer''s Report on the Hon''ble NCLT convened meeting of the Equity Shareholders of Dr. Agarwal''s Health Care Limited held on July 02, 2026
Summary of the Proceedings of the NCLT convened meeting of the Equity Shareholders of Dr Agarwal''s Health Care Limited held on July 02, 2026
Closure of Trading Window pursuant to Dr. Agarwal''s Health Care Limited - Code of Conduct for Prevention of Insider Trading
Re-affirmation and Withdrawal of Credit Rating by CRISIL Ratings Limited with respect to the debt facilities availed by the Company, is enclosed.
Notice convening meeting of the Equity Shareholders of the Company pursuant to the Order of Honble NCLT, Chennai Bench, is attached.
Notice convening the meeting of the Secured Creditors of the Company pursuant to the Order of Honble NCLT, Chennai Bench
Notice convening meeting of the Unsecured Creditors of the Company pursuant to the Order of Honble NCLT, Chennai Bench
Letter providing direct weblink and a static Quick Response Code to the Notice of the meeting of Equity Shareholders and Unsecured Creditors, is attached.
Joint Newspaper Advertisement of the NCLT convened meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Company, is attached
Transcript of the Discussion held on the Audited Financial Results (Consolidated & Standalone) of the Company for the quarter and year ended March 31, 2026, at the analyst call held on ....
Update on Investment in Orbit Health Care ETH PLC by Orbit Healthcare Services (Mauritius) Limited, a wholly owned subsidiary of the Company.
Intimation of Schedule of Analyst / Investors Meet, is attached.
Outcome of the Meeting of the Board of Directors of the Company held on May 21, 2026, is attached.
Allotment of 25,240 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employees Stock Option Scheme 2022
Presentation on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026 is attached
Consolidated and Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.
Link for the Audio recording of the Analyst / Earnings Conference call held on the Audited Financial Results (Consolidated and Standalone) of the Company for the quarter and year ended ....
As per the letter enclosed.
As per the letter enclosed.
As per the letter enclosed.
Dr. Agarwal''s Health Care Limited - Monitoring Agency Report for the quarter ended March 31, 2026, is attached.
Intimation of Analyst / Earnings Conference call to discuss the Audited Financial Results (Standalone & Consolidated) of the Company For The Quarter And Year Ended March 31, 2026, is attached
Dr. Agarwals Health Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Receipt of Order passed by the Hon''ble NCLT, Chennai Bench, in relation to the Scheme of amalgamation between Dr. Agarwal''s Eye Hospital Limited and Dr. Agarwal''s Health Care Limited, is attached
Allotment of 1,50,282 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employees Stock Option Scheme 2022
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026, is enclosed.
Intimation of Cessation of Idearx Services Private Limited as an Associate Company, is attached.
Closure of Trading Window pursuant to Dr. Agarwal''s Health Care Limited - Code of Conduct for Prevention of Insider Trading
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Anosh Agarwal
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Athiya Agarwal
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Athiya Agarwal
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Athiya Agarwal
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Anosh Agarwal
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Athiya Agarwal
Annual Reports
12025
Credit Ratings
6Concalls
6Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Sep 2025
30 Sept 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Held by ETFs
5 ETFs hold AGARWALEYE · sorted by weight
Held by Mutual Funds
21 schemes hold AGARWALEYE · sorted by weight